Galbot is turning China humanoid funding into a full-stack deployment race

Galbot secured more than $300 million in new funding on December 19, 2025, bringing total financing above $800 million and setting a reported $3 billion valuation. The round is part of China's fast-moving humanoid race, but Galbot's event is more specific than a capital headline: the company tied the money to technology development, deployment scale-up, and global expansion across manufacturing, logistics, retail, and healthcare.

The funding followed a June 2025 joint venture agreement with Boyuan Capital, an investment platform under Bosch Group. Bosch China, Boyuan, and Galbot framed the collaboration around embodied intelligence, industrial applications, and commercialization channels. For a humanoid company, that kind of manufacturing-adjacent partner matters through access to industrial workflows, supplier knowledge, and customer environments where robots have to survive real operating requirements.

Galbot describes itself as a full-stack embodied AI company, developing datasets, foundation models, robot hardware, and deployment systems internally. The company has named partners including CATL, Bosch, Toyota, and Hyundai, and says its G1 robots are being deployed across manufacturing, logistics, retail, and healthcare. It has also pointed to Galbot Store deployments in more than 30 cities, warehouse systems operating around the clock for more than a year, and healthcare work with Xuanwu Hospital.

Those claims create a meaningful commercial signal, but the public record is still uneven. Galbot does not disclose paid unit counts by customer, robot-hours by deployment, uptime by site, task success rates, gross margin, or customer-side productivity metrics. The strongest evidence is a combination of capital access, named partner categories, and broad deployment claims rather than a transparent operating dataset.

The competitive field includes UBTECH, AgiBot, Unitree, Fourier, EngineAI, Tesla, Figure, Apptronik, and other Chinese embodied-intelligence companies using large funding rounds to build hardware, model, and deployment capacity at the same time. Galbot's distinction is the attempt to connect foundation-model development, humanoid hardware, industrial partners, and consumer-facing retail deployment into one commercialization path.

The strategic test is whether Galbot can turn China's humanoid capital surge into repeatable field operations rather than disconnected demos across many verticals. If the Bosch-linked industrial channel and reported retail, warehouse, and healthcare deployments convert into measurable robot utilization, Galbot becomes less of a funded humanoid contender and more of a full-stack deployment company for embodied AI in China and beyond.

Have a robotics update Korthos should review? Send news, deployments, product releases, funding rounds, research, or media to tips@korthos.xyz or reach out on X at @agkorthos.